Form 13-F position report

NIAGEN BIOSCIENCE INC

Reported by ALLIANCEBERNSTEIN L P

NAGE CUSIP 171077407 Manager CIK 0001109448

Reported 258,620 shares, up 109,500 (73.4%) from the prior quarter.

Reported value 18.2%; share count 73.4% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q4 2025
Shares 258,620 Quarter-end amount reported
Reported value $1,644,823 Fair value at quarter end
Consecutive quarters held 7 Through Q4 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 110000
2022-03-31 59000
2022-06-30 0
2024-06-30 27437
2024-09-30 36683
2024-12-31 53315
2025-03-31 69345
2025-06-30 725544
2025-09-30 1391290
2025-12-31 1644823
2026-03-31 2054032
2026-06-30 238802
2026-09-30 199874

Quarterly position history

How this manager's reported quarter-end position changed over time.

13 quarters
Quarterly reported position history for NIAGEN BIOSCIENCE INC held by ALLIANCEBERNSTEIN L P.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 68,450 +14,300 (26.4%) < 0.01% $199,874 2026-11-16
Q2 2026 Reduced 54,150 -268,811 (-83.2%) < 0.01% $238,802 2026-08-14
Q1 2026 Added 322,961 +64,341 (24.9%) < 0.01% $2,054,032 2026-05-15
Q4 2025 Added 258,620 +109,500 (73.4%) < 0.01% $1,644,823 2026-02-17
Q3 2025 Added 149,120 +98,770 (196.2%) < 0.01% $1,391,290 2025-11-14
Q2 2025 Added 50,350 +40,300 (401.0%) < 0.01% $725,544 2025-08-14
Q1 2025 Unchanged 10,050 0 (0.0%) < 0.01% $69,345 2025-05-15
Q4 2024 Unchanged 10,050 0 (0.0%) < 0.01% $53,315 2025-02-12
Q3 2024 Unchanged 10,050 0 (0.0%) < 0.01% $36,683 2024-11-14
Q2 2024 New 10,050 +10,050 (0.0%) < 0.01% $27,437 2024-08-14
Q2 2022 Reduced 0 -24,100 (-100.0%) 0 $0 2022-08-15
Q1 2022 Reduced 24,100 -5,200 (-17.7%) < 0.01% $59,000 2022-05-13
Q4 2021 Unchanged 29,300 0 (0.0%) < 0.01% $110,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

197 managers reported NIAGEN BIOSCIENCE INC for Q4 2025.

Managers reporting NIAGEN BIOSCIENCE INC in Q4 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 4,075,709 +98,706 < 0.01% $25,921,508 6 qtrs
VANGUARD GROUP INC Reduced 3,286,498 -735,152 < 0.01% $20,902,127 39 qtrs
Tieton Capital Management LLC Reduced 1,645,093 -1,825 3.58% $10,463,000 36 qtrs
ARROWSTREET CAPITAL LIMITED PARTNERSHIP Added 1,616,752 +179,954 < 0.01% $10,282,543 6 qtrs
UBS Group AG Added 1,411,742 +215,645 < 0.01% $8,978,679 39 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 1,294,863 -604 < 0.01% $8,237,043 39 qtrs
STATE STREET CORPORATION Reduced 1,091,039 -1,671 < 0.01% $6,939,008 32 qtrs
Qube Research & Technologies Ltd Added 1,061,835 +185,605 < 0.01% $6,753,271 5 qtrs
The Goldman Sachs Group Inc Added 954,880 +576,254 < 0.01% $6,073,037 8 qtrs
DIMENSIONAL FUND ADVISORS LP Added 920,370 +194,647 < 0.01% $5,854,029 7 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2025
Filed
February 17, 2026
Filing type
13F-HR
Position type
COM NEW

Voting authority reported

Sole
258,620
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.